Stereotaxis’ PowerAssert Guide Wire Navigates Peripheral CTOs
Stereotaxis Inc. said the FDA cleared its magnetically tipped PowerAssert radiofrequency (RF) guide wire to cross chronic total occlusions (CTOs) in the peripheral vasculature.
Occluded or blocked arteries occur in patients with advanced peripheral arterial disease (PAD), and if left untreated can result in ulcerations and gangrene as well as significantly increased risk of limb loss and death. Eight to 12 million people have PAD, according to the American Heart Association.
Stereotaxis’ magnetically steerable RF guidewire is designed to ablate through CTOs in peripheral arteries. Its Niobe Magnetic Navigation System reportedly directs the guidewire’s distal tip in a very precise manner, allowing for accurate and efficient navigation through difficult to treat regions of the peripheral vasculature and CTOs.
More like this
- FDA Clears Stereotaxis’ PowerAssert Guidewire to Navigate Peripheral CTOs
- Heart Hospital of Austin First to Use Stereotaxis RF PowerAssert to Treat Blocked Arteries
- Stereotaxis Announces First CTO Crossing Procedure With RF PowerAssert Magnetic Guide Wire
- FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs
- Devices Offer New PAD Treatment Options